Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;29(1):2365590.
doi: 10.1080/13510002.2024.2365590. Epub 2024 Jun 11.

Evaluating anticancer activity of emodin by enhancing antioxidant activities and affecting PKC/ADAMTS4 pathway in thioacetamide-induced hepatocellular carcinoma in rats

Hanan M Hassan  1 , Ahmed M Hamdan  2 , Abdullah Alattar  3 , Reem Alshaman  3 , Omar Bahattab  4 , Mohammed M H Al-Gayyar  5   6
Affiliations

Evaluating anticancer activity of emodin by enhancing antioxidant activities and affecting PKC/ADAMTS4 pathway in thioacetamide-induced hepatocellular carcinoma in rats

Hanan M Hassan et al. Redox Rep. 2024 Dec.

Abstract

Emodin is a naturally occurring anthraquinone derivative with a wide range of pharmacological activities, including neuroprotective and anti-inflammatory activities. We aim to assess the anticancer activity of emodin against hepatocellular carcinoma (HCC) in rat models using the proliferation, invasion, and angiogenesis biomarkers. After induction of HCC, assessment of the liver impairment and the histopathology of liver sections were investigated. Hepatic expression of both mRNA and protein of the oxidative stress biomarkers, HO-1, Nrf2; the mitogenic activation biomarkers, ERK5, PKCδ; the tissue destruction biomarker, ADAMTS4; the tissue homeostasis biomarker, aggregan; the cellular fibrinolytic biomarker, MMP3; and of the cellular angiogenesis biomarker, VEGF were measured. Emodin increased the survival percentage and reduced the number of hepatic nodules compared to the HCC group. Besides, emodin reduced the elevated expression of both mRNA and proteins of all PKC, ERK5, ADAMTS4, MMP3, and VEGF compared with the HCC group. On the other hand, emodin increased the expression of mRNA and proteins of Nrf2, HO-1, and aggrecan compared with the HCC group. Therefore, emodin is a promising anticancer agent against HCC preventing the cancer prognosis and infiltration. It works through many mechanisms of action, such as blocking oxidative stress, proliferation, invasion, and angiogenesis.

Keywords: ADAMTS4; Aggrecan; Angiogenesis; ERK5; HO-1; MMP3; Nrf2; PKCδ; VEGF; emodin; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Timeline of the animal treatment in the study.
Figure 2.
Figure 2.
Effect of oral administration of emodin (40 mg/kg, P.O) on both mRNA and protein levels of the antioxidant biomarkers; Nrf2 and HO-1. (a) The relative expression of the hepatic Nrf2 mRNA, (b) the relative hepatic NRF2 protein levels, (c) the relative expression of the hepatic HO-1 mRNA and (d) the relative hepatic HO-1 protein. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. C, control; HCC, hepatocellular carcinoma; HO-1; Heme oxigenase variant 1; Nrf2, nuclear factor erythroid 2-related factor 2.
Figure 3.
Figure 3.
Effect of oral administration of emodin (40 mg/kg, P.O) on oxidative status of the hepatic cells. (a) The relative hepatic tissues of MDA. (b) The relative hepatic tissues of reduced glutathione. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. C, control; HCC, hepatocellular carcinoma; MDA; malondialdehyde.
Figure 4.
Figure 4.
Effect of oral administration of emodin (40 mg/kg, P.O) on the percent survival and hepatic nodules. (a) The percent of the survival of the four groups of the experiment over sixteen weeks. (b) Representative images of livers separated from different treated groups. (c) Relative serum cancer market AFP in tested groups. (d) The average number of hepatic nodules in groups. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. C, control; HCC, hepatocellular carcinoma; AFP, alpha Fetoprotein.
Figure 5.
Figure 5.
Effect of oral administration of emodin (40 mg/kg, P.O) on liver sections stained with Haematoxylin/eosin. (a) Representatives of microscopic pictures of liver sections stained with haematoxylin/eosin showing normally arranged hepatic cords around central veins. Liver section from HCC group show well-differentiated HCC. Cells of HCC are polygonal with distinct cell membranes, an eosinophilic granular cytoplasm and prominent nucleoli (black arrows). Sections from HCC group orally treated with 40 mg/kg emodin show improvement of the structure of hepatocytes. Scale bare represented 50 µm. (b) Mitotic score calculated using high field powers in 10 different areas of each rat. The results of the mitotic figure are presented as the mean ± SE. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. C, control; HCC, hepatocellular carcinoma.
Figure 6.
Figure 6.
Effect of oral administration of emodin (40 mg/kg, P.O) on both mRNA and protein levels of the mitogenic activation biomarkers; PKCδ and ERK5. (a) The relative expression of the hepatic PKCδ mRNA, (b) the relative hepatic PKCδ protein, (c) the relative expression of the hepatic ERK5 mRNA and (d) the relative hepatic ERK5 protein. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. C, control; ERK5, extracellular-signal-regulated kinase 5; HCC, hepatocellular carcinoma; PKCδ; Protein kinase C delta type.
Figure 7.
Figure 7.
Effect of oral administration of emodin (40 mg/kg, P.O) on liver sections stained with anti-ADAMTS4 antibodies. (a) Representative images of hepatic tissues stained with anti-ADAMTS-4 antibodies in different treated groups showing increased staining in the HCC group, which was reduced by treatment with emodin. (b) The positive staining score was determined through immunohistochemistry in ten different fields. Black arrows indicated the areas of positive immune staining. Scale bar represents 100 μm.
Figure 8.
Figure 8.
Effect of oral administration of emodin (40 mg/kg, P.O) on mRNA expression of hepatic ADAMTS4, aggrecans, MMP3 and VEGF. (a) The relative expression of the hepatic ADAMTS-4 mRNA and (b) the relative expression of the hepatic aggrecans mRNA. (c) the relative expression of the hepatic MMP3 mRNA. (d) the relative expression of the hepatic VEGF mRNA. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. ADAMTS4, A disintegrin and metalloproteinase with thrombospondin motifs 4; C, control; HCC, hepatocellular carcinoma; MMP3, matrix metallopeptidase 3; VEGF, vascular endothelial growth factor.
Figure 9.
Figure 9.
Effect of oral administration of emodin (40 mg/kg, P.O) on protein expression of hepatic ADAMTS4, aggrecans, MMP3 and VEGF. (a) Representative images of Western blot analysis of hepatic ADAMTS4, aggrecans MMP3 and VEGV. (b) ROD of Western blot analysis of ADAMTS4 in relation to control. (c) ROD of Western blot analysis of aggrecans in relation to control. (d) ROD of Western blot analysis of MMP3 in relation to control. (e) ROD of Western blot analysis of VEGF in relation to control. * Significant difference as compared with the control groups at p < 0.05. # Significant difference as compared with the HCC group at p < 0.05. ADAMTS4, A disintegrin and metalloproteinase with thrombospondin motifs 4; C, control; HCC, hepatocellular carcinoma; MMP3, matrix metallopeptidase 3; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Samant H, Amiri HS, Zibari GB.. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361–S373. - PMC - PubMed
    1. Elewa MA, Al-Gayyar MM, Schaalan MF, et al. . Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers. Clin Exp Metastasis. 2015 Jun;32(5):479–493. doi:10.1007/s10585-015-9721-6 - DOI - PubMed
    1. Sas Z, Cendrowicz E, Weinhauser I, et al. . Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for New treatment options. Int J Mol Sci. 2022 Mar 29;23(7). - PMC - PubMed
    1. Manzar GS, De BS, Abana CO, et al. . Outcomes and toxicities of modern combined modality therapy with atezolizumab plus bevacizumab and radiation therapy for hepatocellular carcinoma. Cancers (Basel). 2022 Apr 9;14(8). - PMC - PubMed
    1. Ferlay J, Colombet M, Soerjomataram I, et al. . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941–1953. doi:10.1002/ijc.31937 - DOI - PubMed

MeSH terms

LinkOut - more resources

-